MedTrace Logo

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

NCT05059158 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-07-04

No results posted yet for this study

Summary

The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.

Conditions

  • Alzheimer's Disease (AD)

Interventions

RADIATION

positron emission tomography (PET)

18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Robert Perneczky, Prof.Dr.med. · Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2025-09-30
Completion
2025-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059158 on ClinicalTrials.gov